Categories
Blood Cancer

BELINDA: Tisagenlecleucel in B-cell NHL [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, discusses results from the Phase III BELINDA trial (NCT03570892), which assessed tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with aggressive B-cell non-Hodgkin lymphoma. The primary endpoint, which was event-free survival, was not met, and tisa-cel was not superior to the current standard of care. Dr Bishop highlights the time taken for the therapy to be administered, bridging therapy, and the dosage of lymphodepleting chemotherapy to be factors affecting the trial results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The role of CAR-T therapy in hematologic malignancies [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, describes advances in chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Data from the JULIET (NCT02445248), TRANSFORM (NCT03575351), BELINDA (NCT03570892), ZUMA-1 (NCT02348216), and ZUMA-7 (NCT03391466) trials have demonstrated CAR T-cell therapy as a promising frontline therapy in non-Hodgkin lymphoma. Dr Bishop additionally highlights updates in multiple myeloma and acute lymphoblastic leukemia (ALL), as well as strategies to manage CAR T-cell toxicity. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Concurrent pembrolizumab and chemotherapy in classical Hodgkin lymphoma [Video]

Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses concurrent pembrolizumab, an anti-PD⁠-⁠1 monoclonal antibody, with AVD (doxorubicin, vinblastine, and dacarbazine) in patients with classical Hodgkin lymphoma (cHL). The treatment regimen displayed promising efficacy and safety and in patients. However, the interim-positron emission tomography (PET) scan results did not align with the high progression-free survival rates observed, and cell-free DNA (cfDNA) may predict outcomes more accurately. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

PD-L1 inhibitors in r/r Hodgkin lymphoma [Video]

Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, describes current treatment options for patients with relapsed/refractory Hodgkin lymphoma who have progressed or are ineligible for transplant. Whilst PD-L1 inhibitors such as pembrolizumab and nivolumab have shown to efficacious in patients, producing durable responses remains a barrier. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Treating TP53 mutant mantle cell lymphoma in the BOVen trial [Video]

Patients with TP53 mutant mantle cell lymphoma (MCL) represent an unmet need and there care no current frontline standard of care for these high risk patients. Anita Kumar, MD, Memorial Sloan Kettering, Short Hills, NJ, presents results from the Phase II BOVen trial (NCT03824483), which investigated zanubrutinib, obinutuzumab, and venetoclax in patients with TP53 mutant MCL. Two cycles of zanubrutinib and obinutuzumab were initially administered, followed by venetoclax. The regimen was well tolerated and displayed preliminary efficacy, with a majority of patients being in ongoing remission. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Novel immunotherapy combinations in Hodgkin lymphoma [Video]

Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, discusses novel immunotherapy approaches currently being evaluated in Hodgkin lymphoma. Pembrolizumab in combination with gemcitabine-based chemotherapy or the ifosfamide, carboplatin, etoposide (ICE) regimen is a promising salvage therapy, and pembrolizumab with doxorubicin, vinblastine, and dacarbazine (AVD) is another potential regimen for frontline therapy. Nivolumab and ruxolitinib is an additional combination that may sensitize patients with relapsed/refractory Hodgkin lymphoma to immunotherapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The value of MRD assessment in lymphoma [Video]

Anita Kumar, MD, Memorial Sloan Kettering, Short Hills, NJ, describes the significance of monitoring minimal residual disease (MRD) in lymphoma. MRD detection can enable accurate evaluation of treatment response and help guide patients to the right treatment path. In the case of the Phase II BOVen trial (NCT03824483), which investigated zanubrutinib, obinutuzumab, and venetoclax in patients with TP53 mutant mantle cell lymphoma (MCL), patients who were MRD positive continued treatment. Dr Kumar additionally highlights the need for more research to evaluate the role of MRD in diffuse large B-cell lymphoma (DLBCL) surveillance. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The future of lymphoma therapies [Video]

Mahmoud Elsawy, MB BCh, MSc, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, discusses the latest advancements in the field of lymphoma research and treatment. He highlights the development of immunotherapies including chimeric antigen receptor (CAR) T-cell therapy, which will enable more durable responses. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Advancements in the field of Hodgkin lymphoma [Video]

Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, describes future developments in the Hodgkin lymphoma treatment landscape. Immunotherapy is playing an increasingly important role within Hodgkin lymphoma treatment. Brentuximab vedotin has demonstrated superior progression-free survival compared to conventional chemotherapies such as gemcitabine. Monoclonal antibodies including nivolumab and pembrolizumab are being recommended as combination therapies with chemotherapy or first-line therapy for treatment-naïve patients and Dr Desai additionally highlights the need for further treatment options for patients who progress on immunotherapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

PD-1 blockade in Hodgkin lymphoma: moving up the ranks [Video]

Enhanced PD-1 signaling observed in classical Hodgkin lymphoma (cHL) and primary mediastinal large B-cell lymphoma (PMBL) led to the evaluation of PD-1 blockade as a new treatment option. Patients with cHL and PMBL have since shown some of the highest response rate to this approach, enabling substantial progress over the last decade. Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, talks on how the use of PD-1 blockade has developed over time, making its way from relapsed/refractory settings to frontline treatment. Studies have shown the addition of PD-1 blockade to standard treatments to improve outcomes in every circumstance and thus, these approaches are now being investigated in randomized clinical trials for frontline treatment and at first relapse. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Maintenance nivolumab in post-stem cell transplant Hodgkin lymphoma [Video]

Nirav N. Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses data from the single-arm Phase II trial (NCT03436862) of nivolumab, an anti-PD-1 monoclonal antibody, as maintenance therapy in patients with Hodgkin lymphoma who have undergone autologous stem cell transplant. Maintenance brentuximab is currently the standard of care and 37 patients were enrolled in the trial to receive nivolumab. Whilst some patients discontinued treatment due to adverse events, progression-free survival was 92.1% and overall survival was 100% after a 9 month follow-up. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Molecules versus cells for Hodgkin lymphoma management [Video]

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, discusses the use of immunological molecules versus cellular therapy in the management of Hodgkin Lymphoma. A plethora of data is emerging that demonstrates the potential of numerous agents, including CAR T-cells, bispecific antibodies, and other immunologically active agents. Prof. Ansell comments that currently, one category has not shown to be superior than the other, with exciting data coming out to support the use of both. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.